Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats

Miyu Suyoshi1 · Masaki Fukunaga1 · Mizue Mei1 · Atsushi Nakajima2 · Gaku Tanaka2 · Takayo Murase2 · Yuki Narita1,3 · Sumio Hirata1,3 · Daisuke Kadowaki1,3,4

Received: 21 August 2018 / Accepted: 10 March 2019 / Published online: 20 March 2019
© The Author(s) 2019

Abstract
Background  Constipation is frequently observed in patients with chronic kidney disease (CKD). Lactulose is expected to improve the intestinal environment by stimulating bowel movements as a disaccharide laxative and prebiotic. We studied the effect of lactulose on renal function in adenine-induced CKD rats and monitored uremic toxins and gut microbiota.

Methods  Wistar/ST male rats (10-week-old) were fed 0.75% adenine-containing diet for 3 weeks to induce CKD. Then, they were divided into three groups and fed as follows: control, normal diet; and 3.0- and 7.5-Lac, 3.0% and 7.5% lactulose-containing diets, respectively, for 4 weeks. Normal diet group was fed normal diet for 7 weeks. The rats were observed for parameters including renal function, uremic toxins, and gut microbiota.

Results  The control group showed significantly higher serum creatinine (sCr) and blood urea nitrogen (BUN) 3 weeks after adenine feeding than at baseline, with a 8.5-fold increase in serum indoxyl sulfate (IS). After switching to 4 weeks of normal diet following adenine feeding, the sCr and BUN in control group remained high with a further increase in serum IS. In addition, tubulointerstitial fibrosis area was increased in control group. On the other hand, 3.0- and 7.5-Lac groups improved sCr and BUN levels, and suppressed tubulointerstitial fibrosis, suggesting preventing of CKD progression by lactulose. Lac groups also lowered level of serum IS and proportions of gut microbiota producing IS precursor.

Conclusion  Lactulose modifies gut microbiota and ameliorates CKD progression by suppressing uremic toxin production.

Keywords  Lactulose · Renal function · CKD · Uremic toxin · Gut microbiota

Introduction

The estimated prevalence of chronic kidney disease (CKD) is 8–16% worldwide, and Japan has also highest prevalence [1]. Further, concerns over the prevalence of CKD are increasing because its onset and progression have been attributed to aging and modern lifestyles in recent years [2]. Progression of CKD causes various pathologic conditions, including constipation due to dietary fiber insufficiency induced by restricted potassium intake and adverse reactions to potassium binders or other oral medications that induce constipation [3]. Bowel control is one of the key points from the perspective of maintaining or improving the patient’s quality of life (QOL).

Interestingly, a recent study in adenine-induced CKD mice reported that lubiprostone, a chloride channel activator used for chronic constipation, not only stimulates bowel movement but also improves the intestinal environment and suppresses the worsening of renal dysfunction by reducing the accumulation of uremic toxins [4].

On the other hand, lactulose reaches the large intestine in its unchanged form when administered orally. It helps retain intestinal water and electrolytes by increasing the osmotic pressure in the lower intestinal tract. Higher levels
of intestinal water soften the intestinal content making it easier to move with looser stool and frequent bowel movements. Compared with sennosides and other irritant cathartics, lactulose as a laxative has less adverse reactions such as abdominal pain and is widely used as an osmotic laxative in other countries [5].

While lactulose is expected to further improve the intestinal environment by its dual function as a disaccharide laxative that stimulates bowel movement and as a prebiotic [6], few reports of its potential effect on the renal function are available. Here, we report our study in adenine-induced CKD rats evaluating the effects of lactulose on the renal function, uremic toxins, and gut microbiota.

Materials and methods

Reagents

Crystalline lactulose (purity ≥ 97%) was provided by Sanwa Kagaku Kenkyusho Co., Ltd. (Mie, Japan). Adenine was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Indoxyl sulfate (IS) potassium salt and 3-indoxyl sulfate-d4 (IS-d4) potassium salt were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA) and Toronto Research Chemicals (Toronto, Canada), respectively. Trimethylamine N-oxide (TMAO) dihydrate and trimethylamine N-oxide-d9 (TMAO-d9) were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan) and Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA), respectively. p-Cresyl sulfate (PCS) was synthesized according to a published method [7].

Experimental animals

The Wistar/ST male rats (9-week-old) purchased from Japan SLC, Inc. (Shizuoka, Japan). The animals were individually kept in an animal facility under controlled conditions, 23 ± 2 °C and relative humidity of 55 ± 10% under 12-h light/dark cycle with free access to feed (CE-2, CLEA Japan, Inc., Tokyo, Japan) and water. This study was approved by the institutional animal experiment committee at Kumamoto University and Sanwa Kagaku Kenkyusho Co., Ltd.

Animal study

The study design is shown in Fig. 1. After 1-week acclimation, the rats were divided into two groups and fed either normal feed CE-2 (normal group, \( n = 12 \)) or 0.75% adenine-containing CE-2 feed (\( n = 36 \)) for 3 weeks. Then, the adenine-containing feed groups were divided into three groups (\( n = 12 \) each): control (fed CE-2 solid feed) and 3.0- and 7.5-Lac (fed CE-2 solid feed supplemented with lactulose at 3.0% and 7.5%, respectively) with comparable serum creatinine (sCr), BUN, serum IS, and body weight. The animals were observed for 4 weeks, and a normal group was fed normal CE-2 feed.

Blood samples were obtained under isoflurane anesthesia, from the subclavian vein before (week − 3) and 3 weeks after feeding the adenine-containing diet (week 0) and from the inferior vena cava on the last day of the normal or lactulose-containing diet (week 4). Blood samples were centrifuged at 3000×g for 10 min at 4 °C to separate the serum. sCr, BUN and other serum chemistry parameters were determined using an automatic analyzer (Hitachi 7180, Hitachi High-Technologies Corp., Tokyo, Japan). At 4 weeks, blood samples were collected in sampling tubes containing EDTA-2K and analyzed using a multi-parameter automatic hematology analyzer (XT-2000iV, SYSMEX Corp., Hyogo, Japan). The kidneys were weighed and sampled for histopathological examination at week 4.

Measurement of oxidative stress markers

Serum concentrations of malondialdehyde (MDA) were determined using thiobarbituric acid reactive substances (TBARS) assay kit (Funakoshi Co., Ltd., Tokyo, Japan). Serum concentrations of advanced oxidation protein products (AOPPs) were determined according to a method described by Witko-Sarsat et al. [8]. Serum samples were diluted fivefold in phosphate-buffered saline (PBS) and dispensed in 200-µL volumes in microplates, mixed with 20 µL acetic acid and 10 µL 1.16 M potassium iodide, and analyzed using a microplate reader (iMark, Bio-Rad Laboratories, Inc., Hercules, CA, USA.) to determine the absorbance at 340 nm.

Measurement of antioxidant markers

Serum thiol content was determined using the 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) method [9, 10]. Buffer A was prepared by mixing 100 mM potassium phosphate buffer (KPB, pH 7.0) and 1 mM diethylenetriamine pentaacetate (DTPA), and buffer B was prepared by mixing 10 mM buffer A and 2.0 mg DTNB. Serum samples were dispensed in 20 µL volumes in microplates and mixed with 100 µL buffer A (blank wells) or 100 µL buffer B (sample wells), incubated for 15 min, and analyzed by measuring the absorbance at
405 nm. The thiol content was calculated based on differences in absorbance readings between the sample and blank wells.

Serum reduced and oxidized glutathione (GSH and 
GSSG, respectively) were determined using a 
GSSG/GSH quantification kit (Dojindo Co., Ltd., Kumamoto, Japan) according to the supplier’s instructions.

**Measurement of IS, PCS, and TMAO**

To measure IS and TMAO, serum samples were deproteinized with an ethanol solution containing an internal standard and analyzed using liquid chromatography–mass spectrometry (LC–MS) [11]. The internal standards were IS-d₄, IS, and TMAO-d₉ TMAO. A high-performance LC (HPLC) system (Acquity UPLC®, Waters Corp., Milford, MA, USA) and a mass spectrometer (LTQ-Orbitrap, Thermo Fisher Scientific GmbH, Bremen, Germany) were used.

To measure PCS, serum samples were deproteinized with methanol and analyzed using HPLC [12]. An HPLC system equipped with an autosampler (AS-950, JASCO Corp., Tokyo, Japan), a pump (PU-980, JASCO Corp., Tokyo, Japan), and a fluorescence detector (RF-10A, Shimadzu Corp., Kyoto, Japan) was used.

**Histopathological examination of kidney tissue**

Each kidney harvested at week 4 was fixed in 10% buffered formalin, paraffin embedded, cut into thin sections, and stained using Masson’s trichrome (MT). Stained sections were observed using a fluorescence microscope (BZ-X710, KEYENCE Corp., Osaka, Japan) and the tubulointerstitial fibrosis area was quantitated using a BZ-X analyzer.

**Quantitative real-time polymerase chain reaction (PCR) analysis**

RNA was extracted using SYBER® premix Ex TaqTM II (TaKaRa Bio Inc. Japan). cDNA was synthesized using PC-818S (ASTEC CO. LTD., Japan) as a thermal cycler. The sequences of the primers used in this study were as follows:
rat transforming growth factor (TGF)-β, forward 5′-TAC AACAGCACC CGGACC-3’, reverse 5′-TGCGTGTGT GCGGTCACCA-3’; rat GAPDH, forward 5′-CCCTGGA GAAACCTGCA AAGTATG-3’, reverse 5′-TTGAAGTCA CAGGACACCTG-3’.

Analysis of gut microbiota and short-chain fatty acid

Fecal samples were collected via forcible bowel movement by massaging the abdomen and anus of the rats at week −3, 0, and 4. The fecal samples were subjected to terminal restriction fragment length polymorphism (T-RFLP) analysis of gut microbiota. Short-chain fatty acid concentrations were determined by analyzing the cecal content samples collected on the last day of the lactulose-containing diet using LC with post-column pH-buffered electroconductivity detection. Gut microbiota and short-chain fatty acid analyses were performed at TechnoSuruga Laboratory Co., Ltd. (Shizuoka, Japan).

Statistical analysis

The data were expressed as mean ± SD and compared using an analysis of variance (ANOVA) with Tukey–Kramer test and differences. p < 0.05 was considered statistically significant. Serum IS and sCr or BUN were analyzed for correlation using single regression analysis.

Result

Body weight, food consumption, and hematology

Time-course profiles of body weight and food consumption at week −3, 0, and 4 are shown in Fig. 2. Hematology and serum chemistry findings at week 4 are summarized in Table 1. Three animals died during the study. Two died at week 3 and week 4 in the control group, and the other at

| Table 1 Effects of lactulose on hematology and serum chemistry findings of adenine-induced chronic kidney disease (CKD) rats at week 4 |
|-----------------|--------|--------|
|                  | Normal | CKD    |
|                  | Control | 3.0 Lac | 7.5 Lac |
| RBC (10⁶/µL)    | 907.8 ± 31.0 | 551.8 ± 78.9** | 617.2 ± 57.7**.ø | 661.5 ± 47.7**.ø |
| WBC (10⁶/µL)    | 107.4 ± 18.6 | 119.4 ± 21.3 | 166.8 ± 38.8**.ø | 171.3 ± 17.7**.ø |
| HGB (g/dL)      | 16.0 ± 0.3  | 10.0 ± 1.4** | 10.9 ± 1.0**     | 11.8 ± 0.9**.ø  |
| HCT (%)         | 45.8 ± 0.7  | 30.4 ± 4.0** | 33.1 ± 3.7**     | 35.6 ± 3.0**.ø  |
| RET (10⁴/µL)    | 30.9 ± 2.2  | 33.8 ± 9.1** | 40.0 ± 7.9**     | 40.9 ± 7.2**     |
| Na              | 140.9 ± 1.4 | 139.4 ± 3.0 | 138.9 ± 2.1     | 140.1 ± 2.0     |
| K               | 4.7 ± 0.2   | 6.1 ± 0.4** | 6.3 ± 0.9**     | 5.7 ± 0.4**     |
| Cl              | 100.5 ± 1.6 | 98.6 ± 4.1  | 99.7 ± 2.1      | 100.9 ± 2.2     |
| Ca (mg/dL)      | 9.7 ± 0.3   | 8.7 ± 1.4*  | 9.7 ± 0.4ø      | 9.7 ± 0.5ø      |
| IP (mEq/dL)     | 6.2 ± 0.4   | 8.9 ± 1.7** | 7.7 ± 0.7**     | 7.8 ± 1.1**     |
| Albumin (g/dL)  | 2.5 ± 0.1   | 2.2 ± 0.1** | 2.3 ± 0.2**     | 2.3 ± 0.1*      |
| Globulin (g/dL) | 2.9 ± 0.2   | 2.7 ± 0.1*  | 2.7 ± 0.2**     | 2.8 ± 0.1       |
| Albumin/globulin| 0.9 ± 0.04  | 0.8 ± 0.04* | 0.8 ± 0.05      | 0.8 ± 0.04      |
| Total protein (g/dL) | 5.4 ± 0.2 | 4.9 ± 0.3** | 4.9 ± 0.4**     | 5.1 ± 0.1*      |
| AST (IU/L)      | 87.5 ± 12.0 | 63.6 ± 7.4** | 79.1 ± 14.9     | 77.7 ± 23.7     |
| ALT (IU/L)      | 57.7 ± 5.9  | 52.3 ± 7.5  | 47.4 ± 9.9      | 53.6 ± 14.1     |
| LDH (IU/L)      | 410.7 ± 131.5 | 166.7 ± 66.1 | 408.0 ± 372.2   | 337.4 ± 318.8   |
| ALP (IU/L)      | 829.6 ± 152.5 | 883.3 ± 142.6 | 900.1 ± 105.2  | 916.1 ± 100.6   |
| Total bilirubin (mg/dL) | 0.003 ± 0.007 | 0.001 ± 0.003 | 0.004 ± 0.008  | 0.001 ± 0.003   |
| Phospholipids (mg/dL) | 124.9 ± 15.9 | 200.0 ± 31.4** | 187.5 ± 21.1** | 185.7 ± 18.4** |
| TG (mg/dL)      | 59.3 ± 26.6 | 96.0 ± 46.8 | 79.5 ± 34.9     | 57.8 ± 15.8ø    |
| Total cholesterol (mg/dL) | 71.5 ± 11.0 | 133.2 ± 20.3** | 124.5 ± 19.8** | 124.8 ± 15.0ø  |
| CK (IU/L)       | 325.9 ± 148.1 | 152.1 ± 53.9 | 292.2 ± 215.8   | 245.8 ± 169.3   |
| Glucose (mg/dL) | 145.3 ± 19.1 | 130.0 ± 14.1 | 133.6 ± 15.1    | 133.2 ± 12.5    |

Values are expressed as the mean ± SD; n = 10–12/group

* p < 0.05 and ** p < 0.01 vs. normal group, and ø p < 0.05 and øø p < 0.01 vs. control group

RBC red blood cell, WBC white blood cell, HGB hemoglobin, HCT hematocrit, RET reticulocyte, IP inorganic phosphorus, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, ALP alkaline phosphatase, TG triglycerides, CK creatine kinase
week 4 in the 3.0-Lac group. The body weight of the control group decreased rapidly after adenine feeding, followed by a stable level for the rest of adenine feeding. After switching to normal diet following 3 weeks of adenine feeding, the body weight of control group gradually increased. Both of Lac groups exhibited a profile similar to that of the control group. The food consumption showed a sharp decrease after start of adenine feeding, followed by a recovery from 1 week later. The control group showed a further increase in food consumption after switching to a normal diet, followed by a gradual decrease until the study ended. The Lac groups showed a further increase in food consumption after switching to the lactulose-containing diet, followed by a gradual increase until the study ended. Additionally, no constipation and no diarrhea were observed in any groups during the study period. Hematologically, the red blood cell count, hemoglobin, and hematocrit levels of the control group markedly decreased compared with the normal group, while the Lac group parameters improved relative to the control in a dose-dependent manner. Moreover, the hypocalcemia that observed in control group improved at the same level as normal group by Lac. The white blood cell count was increased by the lactulose diet.

**Renal function**

Time-course profiles of sCr and BUN at week −3, 0, and 4 are shown in Fig. 3a, b, respectively. Three weeks of the adenine-containing diet caused significant increase in sCr and BUN levels. The control group continued to have high sCr and BUN levels (2.15 and 128.5 mg/dL at week 4, respectively) during a period from week 0 to 4. The 3.0- and 7.5-Lac groups showed improved sCr level (1.54 and 1.36 mg/dL, respectively) at week 4 compared with levels before lactulose diet (week 0). The 7.5-Lac group showed significantly lower levels than the control group did \( (p<0.01) \). The BUN level of the 7.5-Lac group was also significantly lower than that of the control group (81.1 mg/dL, \( p<0.01 \)).

**Uremic toxins**

The time-course profiles of serum IS at week −3, 0, and 4 are shown in Fig. 4a. The control group serum IS level at week 0 was higher by approximately 8.5-fold than the level at week −3. The control group showed further increased serum IS levels at week 4 compared with the level at week 0. On the other hand, both of Lac groups showed decreased serum IS levels compared with the level before the lactulose diet. Both of Lac groups showed significantly lower levels than the control group did \( (p<0.01) \). Single regression analyses of serum IS and sCr or BUN levels at week 4 showed high correlations for both analyses \( (r=0.88, r=0.90, \text{respectively}; \text{Fig. 4d, e}) \).

**Oxidative stress**

The serum AOPPs level, as an oxidative stress marker at week 4, significantly decreased in the 7.5-Lac group compared with that in the normal group (Fig. 5a). Serum MDA levels were comparable across the four groups (Fig. 5b). Serum thiol content, determined as a measure of antioxidant capacity, was decreased in the control group and significantly improved in the 7.5-Lac group (Fig. 5c). Serum GSH levels were significantly higher in the 7.5-Lac group than in the normal group, and the GSH/GSSG ratio exhibited a similar trend (Fig. 5d, e).
Kidney weight and morphological changes

Data of the relative kidney weight per unit body weight at week 4 are shown in Fig. 6a. Representative micrographs of MT-stained kidney tissues at week 4 are presented for each group in Fig. 6b and the data of the relative tubulointerstitial fibrosis area are shown in Fig. 6c.

The relative kidney weight and relative fibrosis area at week 4 remarkably increased compared with that in the normal group. These increases were significantly suppressed...
in the Lac groups. Quantitative real-time PCR indicated a slight decrease of TGF-β, but not significantly (Fig. 6d).

**Gut microbiota and short-chain fatty acids**

Peak area ratios of the entire microbiota and individual bacterial taxa at week 4 are compared across the groups in Fig. 7a, b. The *Bacteroides* [13] and *Clostridium* cluster XI [14], which both include many bacterial species producing indole, a precursor of IS, showed decreased peak area ratios in the Lac groups compared with the control group. The *Bifidobacterium* peak area ratio was increased more in the Lac groups than in the control group. Quantitative analysis of gut microbiota using 4′,6-diamidino-2-phenylindole (DAPI) staining did not indicate a difference among the four groups (data not shown).

The quantitative results of short-chain fatty acids in the cecal content at week 4 (Fig. 7c) did not demonstrate a meaningful difference between the control and the normal groups. No apparent changes were induced by the lactulose diet.

**Discussion**

The adenine-induced CKD rat was reported by Yokozawa et al. [15] as a renal failure model. Orally ingested adenine is rapidly metabolized to 2,8-dihydroxyadenine, which is
deposited and crystallized in the microvilli and the apical domains of the epithelia in proximal renal tubules, causing renal tubule and interstitium degeneration and progression to renal failure [16]. The control rats, which were initially fed a 0.75% adenine-containing diet for 3 weeks and then switched to normal diet for 4 weeks, showed markedly increased sCr and BUN compared with levels before adenine feeding. The rats also exhibited significant tubulointerstitial fibrosis and anemia. These results indicated that the model was a progressed stage of CKD [17].

We also speculated that adenine-induced tubular disorder suppressed renal excretion of uremic toxins [18–20], leading to increase of serum IS, PCS, and TMAO levels even after 4 weeks on normal diet. Additionally, adenine-induced CKD rats are reported to have intestinal permeability increase [21] which can contribute to increase of these uremic toxins as

Fig. 6 Effects of lactulose on relative kidney weights (a) and renal fibrosis (b–d) in adenine-induced chronic kidney disease (CKD) rats. Representative micrographs showing Masson’s trichrome (MT) staining (b). Scale bar, 200 µm. Fibrosis was digitally quantified and is shown as percentage of blue area of MT stain in kidney section (c). TGF-β mRNA expression was examined with quantitative PCR (d). The expression levels were normalized to the levels in the kidney from the normal rats. Values are expressed as mean ± SD; n = 10–12/group. **p < 0.01 vs. normal group, †p < 0.05 and ††p < 0.01 vs. control group, and †††p < 0.01 vs. 3.0-Lac group.
Because elevated levels of IS and PCS are known to exacerbate tubular disorder [22, 23], higher IS, and PCS levels in our study likely promoted CKD progression. In contrast, both Lac groups showed decreased levels of serum IS compared with the level before the lactulose diet, and the difference was significant compared with the control group. In the formation of IS, tryptophan from dietary protein is metabolized by enteric bacteria into indole, which is absorbed from the portal vein, conjugated in the liver, and enters the circulation [24]. Based on our observation, the proportion of bacterial taxa containing many indole-producing bacterial species was reduced by lactulose compared with the control group. The decreased serum IS induced by lactulose was likely attributable to suppressed metabolic conversion into indoles in the intestine. Furthermore, the high correlation between serum IS and creatinine or BUN supports that lactulose improved the renal function by reducing serum IS levels. Both Lac groups also exhibited significantly lower serum PCS levels than the control group did. PCS is converted from tyrosine via a similar route to IS [24]. Therefore, the lactulose-induced decrease in serum PCS seemed to also contribute to improving the renal function. Spherical adsorptive carbon used as an oral medication absorbs indole and p-cresol in the intestine reduces serum levels of IS and PCS [25], and its efficacy for the treatment of CKD has been demonstrated [26]. Thus, lactulose is expected to be beneficial for patients with CKD, similar to spherical adsorptive carbon.

In addition, IS induces abnormal regulation of oxygen metabolism in renal tubules and suppresses erythropoietin production [27]. The dose-dependent improvement of the red blood cell count, hemoglobin, and hematocrit levels in the lactulose diets suggests the contribution of suppressed erythropoietin production.

IS and PCS are also involved in oxidative stress and renal fibrosis. IS enters the cell via organic anion transporter (OAT) and induces the production of reactive oxygen species (ROS) by NADPH oxidase [28]. ROS stimulate the expression of various cytokines such as TGF-β and induce epithelial-to-mesenchymal transition (EMT), promoting renal fibrosis [29]. PCS also promotes renal disorder by activating NADPH oxidase to generate ROS, which produces fibrosis-related factors including TGF-β and stimulates tubular degeneration and tubulointerstitial fibrosis [30]. In present study, the lactulose-induced decrease in IS and PCS seemed to contribute to suppress tubulointerstitial fibrosis.
Fig. 7 (continued)

(b) Bifidobacterium, Lactobacillales, Bacteroides

Peak area ratio (%)

Prevotella, Clostridium cluster IV, Clostridium subcluster XIVa

Peak area ratio (%)

Clostridium cluster XI, Clostridium cluster XVIII

Peak area ratio (%)

(c) Short chain fatty acids in feces (mg/g)

Normal, Control, 3.0-Lac, 7.5-Lac

Short chain fatty acids: Propionate, Isobutyric, Butyrate, Lactic, Isobutyric, n-Butyric, n-Valeric, Total

* Significantly different from normal, ** significantly different from control, †† significantly different from 3.0-Lac, # significantly different from 7.5-Lac
Moreover, our findings showed that an antioxidant thiol was increased and TGF-β mRNA was slightly decreased. However, further investigations, such as oxidative stress experiments would be needed to clarify the mechanism of lactulose.

In conclusion, our results indicated that lactulose altered the intestinal environment as a prebiotic and, thereby, suppressed uremic toxin production, consequently suppressing the renal disorder and tubulointerstitial fibrosis progression. The present findings are important because modification of the intestinal environment using prebiotics, including lactulose, could be a novel therapeutic approach in preventing CKD progression.

Acknowledgements This study was supported in part by grants from JSPS (KAKENHI: 18K06774) and the KUMAYAKU Alumni Research Fund.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:620–72.
2. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.
3. Yasuda G, Shibata K, Takizawa T, Ikeda Y, Tokita Y, Umemura S, et al. Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis. 2002;39:1292–9.
4. Mishima E, Fukuda S, Shima H, Hirayama A, Akiyama Y, Takeuchi Y, et al. Alteration of the intestinal environment by lactulose is associated with amelioration of adenosine-induced CKD. J Am Soc Nephrol. 2015;26:1787–94.
5. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60:209–18.
6. Bothe MK, Maathuis AJH, Bellmann S, van der Vossen JMBM, Berressem D, Koehler A, et al. Dose-dependent prebiotic effect of lactulose in a computer-controlled in vitro model of the human large intestine. Nutrients. 2017;9:E767.
7. Feigenbaum J, Neuberg CA. Simplified method for the preparation of aromatic sulfuric acid esters. J Am Chem Soc. 1941;63:3529–30.
8. Small DM, Coombe JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology. 2012;17:311–21.
9. Ishima Y, Hiroyama S, Kragh-Hansen U, Maruyama T, Sawa T, Akaite T, et al. One-step preparation of S-nitrosated human serum albumin with high biological activities. Nitric Oxide. 2010;23:121–7.
10. Gryzunov YA, Arroyo A, Vigne J-L, Zhao Q, Tyurin VA, Hubel CA, et al. Binding of fatty acids facilitates oxidation of cysteine-34 and converts copper–albumin complexes from antioxidants to prooxidants. Arch Biochem Biophys. 2003;413:53–66.
11. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T. Correlation between serum levels of protein-bound uremic toxins in hemodialysis patients measured by LC/MS/MS. Mass Spectrom (Tokyo). 2013;2:0017.
12. Miyamoto Y, Watanabe H, Noguchi T, Kotani S, Nakajima M, Kadowaki D, et al. Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney. Nephrol Dial Transplant. 2011;26:2498–502.
13. Devlin AS, Marcel D, Dodd D, Nayfach S, Plummer N, Meyer T, et al. Modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe. 2016;20:709–15.
14. Elsdon SR, Hilton MG, Waller JM. The end products of the metabolism of aromatic amino acids by Clostridia. Arch Microbiol. 1976;107:283–8.
15. Yokozawa T, Oura H, Okada T. Metabolic effects of dietary purine in rats. J Nutr Sci Vitaminol (Tokyo). 1982;28:519–26.
16. Claramunt D, Gil- Peña H, Fuente R, García-López E, Loredo V, Hernández-Frias O, et al. Chronic kidney disease induced by adenine: a suitable model of growth retardation in uremia. Am J Physiol. 2015;309:F57–62.
17. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238–52.
18. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshio T. Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake. Br J Pharmacol. 2002;135:555–63.
19. Watanabe H, Sakaguchi Y, Sugimoto R, Kaneko K, Iwata H, Kotani S, et al. Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin. Clin Exp Nephrol. 2014;18:814–20.
20. Wu W, Bush KT, Nigam SK. Key Role for the organic anion transporters, OAT1 and OAT3, in the in vivo handling of uremic toxins and solutes. Sci Rep. 2017;7:9399.
21. Liang S, Liu S, Liu H, He X, Sun L, Chen L, et al. Homocysteine aggravates intestinal epithelial barrier dysfunction in rats with experimental uremia. Kidney Blood Press Res. 2018;43:1516–28.
22. Miyazaki T, Ise M, Os H, Niwa T. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl. 1997;62:15–22.
23. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepens E, et al. Free p-cresyl sulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant. 2010;25:1183–91.
24. Mishima E, Fukuda S, Mukawa C, Yuru A, Kanemitsu Y, Matsumoto Y, et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 2017;92:634–45.
25. Sato E, Saigusa D, Mishima E, Uchida T, Muraki T, Takeuchi Y, et al. Alteration of the intestinal environment by lactulose is associated with amelioration of adenosine-induced CKD. J Am Soc Nephrol. 2015;26:1787–94.
26. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, et al. Effect of a bone morphogenic protein of the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54:459–67.
27. Chiang C-K, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011;91:1564–71.

28. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-κB and free radical in proximal tubular cells. Kidney Int. 2003;63:1671–80.

29. Sun C-Y, Chang S-C, Wu M-S. Uremic toxins induce kidney fibrosis by activating intrarenal renin–angiotensin–aldosterone system associated epithelial-to-mesenchymal transition. PLoS One. 2012;7:e34026.

30. Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013;83:582–92.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.